Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American States Water Company (AWR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

American States Water CompanyTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

American States Water Company vs Recursion Pharmaceuticals Inc — how do they compare? American States Water Company trades at $87.57 (market cap $3.47B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: American States Water Company is the larger of the two by market cap, and American States Water Company pays a 2.49% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AWRRXRX
Market Cap
$3.47B$1.81B
Sector
UtilitiesHealth
52-Week High
$89.28$6.79
52-Week Low
$70.10$2.84
Enterprise Value
$4.37B$1.33B
Dividend Yield
2.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American States Water Company

American States Water (AWR) trades at $87.83, up 1.46% today, with strong technical momentum as moving averages signal bullish alignment. The company maintains robust fundamentals with 20.52% net income margin and consistent dividend growth, recently increasing its quarterly payout by 8.2%. Recent Q2 2026 earnings beat expectations at $1.09 per share, driven by water rate increases and operational gains across business segments.

Outlook remains stable with revenue growth and dividend reliability, though valuation multiples appear elevated versus utilities peers. Key risks include regulatory dependence on rate approvals and competitive pressures. Analyst sentiment is mixed with 20% buy ratings amid concerns about current price levels relative to earnings potential.

Recursion Pharmaceuticals Inc

RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.

Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American States Water Company

American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.

Read more on AWR

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX